Daratumumab for the treatment of multiple myeloma.
作者： Cyrille Touzeau , Philippe Moreau
DOI: 10.1080/14712598.2017.1322578
关键词: Pomalidomide 、 Daratumumab 、 Immunotherapy 、 Monoclonal antibody 、 Internal medicine 、 Dexamethasone 、 Immunology 、 Bortezomib 、 Multiple myeloma 、 Lenalidomide 、 Oncology 、 Medicine
摘要: ABSTRACTIntroduction: Proteasome inhibitors and immunomodulatory drugs have contributed to the dramatic improvement in survival for patients with myeloma over past decades. However, disease typically relapses new classes of are needed. In 2015, two monoclonal antibodies were approved treatment relapsed multiple myeloma, immunotherapy has rapidly become indispensable management patients.Areas covered: Here, authors discuss published data regarding mechanism action, safety clinical efficacy CD38-targeted antibody daratumumab myeloma.Expert opinion: Daratumumab is indicated who received at least 3 prior therapies, including bortezomib, lenalidomide pomalidomide. 2016, combination dexamethasone, or bortezomib dexamethasone was ha...
sci-hub.se 参考文章(42)
Philippe Moreau, Cyrille Touzeau, Multiple Myeloma: From Front-Line to Relapsed Therapies American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. ,vol. 35, pp. 504- 511 ,(2015) , 10.14694/EDBOOK_AM.2015.35.E504
Marije B Overdijk, Sandra Verploegen, Marijn Bögels, Marjolein van Egmond, Jeroen J Lammerts van Bueren, Tuna Mutis, Richard WJ Groen, Esther Breij, Anton CM Martens, Wim K Bleeker, Paul WHI Parren, Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs. ,vol. 7, pp. 311- 320 ,(2015) , 10.1080/19420862.2015.1007813
Claudia I. Chapuy, Rachel T. Nicholson, Maria D. Aguad, Bjoern Chapuy, Jacob P. Laubach, Paul G. Richardson, Parul Doshi, Richard M. Kaufman, Resolving the daratumumab interference with blood compatibility testing. Transfusion. ,vol. 55, pp. 1545- 1554 ,(2015) , 10.1111/TRF.13069
Marlies Oostendorp, Jeroen J. Lammerts van Bueren, Parul Doshi, Imran Khan, Tahamtan Ahmadi, Paul W.H.I. Parren, Wouter W. van Solinge, Karen M.K. De Vooght, When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. ,vol. 55, pp. 1555- 1562 ,(2015) , 10.1111/TRF.13150
Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach, Hareth Nahi, Peter Gimsing, Markus Hansson, Monique C. Minnema, Ulrik Lassen, Jakub Krejcik, Antonio Palumbo, Niels W.C.J. van de Donk, Tahamtan Ahmadi, Imran Khan, Clarissa M. Uhlar, Jianping Wang, A. Kate Sasser, Nedjad Losic, Steen Lisby, Linda Basse, Nikolai Brun, Paul G. Richardson, Targeting CD38 with daratumumab monotherapy in multiple myeloma The New England Journal of Medicine. ,vol. 373, pp. 1207- 1219 ,(2015) , 10.1056/NEJMOA1506348
C Fernández de Larrea, , R A Kyle, B G M Durie, H Ludwig, S Usmani, D H Vesole, R Hajek, J F San Miguel, O Sezer, P Sonneveld, S K Kumar, A Mahindra, R Comenzo, A Palumbo, A Mazumber, K C Anderson, P G Richardson, A Z Badros, J Caers, M Cavo, X LeLeu, M A Dimopoulos, C S Chim, R Schots, A Noeul, D Fantl, U-H Mellqvist, O Landgren, A Chanan-Khan, P Moreau, R Fonseca, G Merlini, J J Lahuerta, J Bladé, R Z Orlowski, J J Shah, Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group Leukemia. ,vol. 27, pp. 780- 791 ,(2013) , 10.1038/LEU.2012.336
Yu-Tzu Tai, Myles Dillon, Weihua Song, Merav Leiba, Xian-Feng Li, Peter Burger, Alfred I. Lee, Klaus Podar, Teru Hideshima, Audie G. Rice, Anne van Abbema, Lynne Jesaitis, Ingrid Caras, Debbie Law, Edie Weller, Wanling Xie, Paul Richardson, Nikhil C. Munshi, Claire Mathiot, Hervé Avet-Loiseau, Daniel E. H. Afar, Kenneth C. Anderson, Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu Blood. ,vol. 112, pp. 1329- 1337 ,(2008) , 10.1182/BLOOD-2007-08-107292
Inger S. Nijhof, Richard W.J. Groen, Willy A. Noort, Berris van Kessel, Regina de Jong-Korlaar, Joost Bakker, Jeroen J.L. van Bueren, Paul W.H.I. Parren, Henk M. Lokhorst, Niels W.C.J. van de Donk, Anton C.M. Martens, Tuna Mutis, Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib Clinical Cancer Research. ,vol. 21, pp. 2802- 2810 ,(2015) , 10.1158/1078-0432.CCR-14-1813
Shaji K. Kumar, S. Vincent Rajkumar, Angela Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, Steven R. Zeldenrust, David Dingli, Stephen J. Russell, John A. Lust, Philip R. Greipp, Robert A. Kyle, Morie A. Gertz, Improved survival in multiple myeloma and the impact of novel therapies Blood. ,vol. 111, pp. 2516- 2520 ,(2008) , 10.1182/BLOOD-2007-10-116129
Fabio Malavasi, Silvia Deaglio, Ada Funaro, Enza Ferrero, Alberto L. Horenstein, Erika Ortolan, Tiziana Vaisitti, Semra Aydin, Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology Physiological Reviews. ,vol. 88, pp. 841- 886 ,(2008) , 10.1152/PHYSREV.00035.2007